

Sister Study Breast Cancer Outcomes and Hormone Receptor Status as of Data Release 4.0

	N (total =2,506)	%
Breast Cancer Subtype for 1st Diagnosis		
Invasive	1,857	74.1
Invasive-ductal	1,361	54.3
Invasive-lobular	170	6.8
Invasive-mixed	126	5.0
Invasive-other/unknown ²	200	8.0
In situ	629	25.1
In situ-ductal	533	21.3
In situ-lobular	76	3.0
In situ-mixed	8	0.3
In situ-other/unknown ³	12	0.5
Invasiveness unknown ⁴	20	0.8
Stage at Diagnosis for 1st Diagnosis		
0	560	24.9
I	1,134	50.3
II	421	18.7
III	120	5.3
IV	19	0.8
Unknown, missing, cannot stage	252	
Estrogen Receptor (ER) Status for 1st Breast Cancer Diagnosis		
Positive	1,807	83.7
Negative	347	16.0
Borderline	6	0.3
Unknown, missing, not performed	346	
Progesterone Receptor (PR) Status for 1st Breast Cancer Diagnosis		
Positive	1,453	70.0
Negative	615	29.7
Borderline	7	0.3
Unknown, missing, not performed	431	
HER2 Amplification Status for 1st Breast Cancer Diagnosis		
Positive	229	13.1
Negative	1,486	85.1
Borderline	31	1.8
Unknown, missing, not performed	760	
Combined ER, PR, HER2 Status		
Triple negative	184	11.1
Triple positive	110	6.6
Mixed positive and negative	1,370	82.3
Unknown, missing, not performed	842	
Incident Breast Cancer Cases by Race/Ethnicity⁵		
Non-Hispanic White	2,161	86.3
Non-Hispanic Black	181	7.2
Hispanic	89	3.5
Other	74	3.0

	N (total =2,506)	%
Age at Breast Cancer Diagnosis		
Under 50 years of age	346	13.9
50-64	1,261	50.6
65 and older	884	35.5
Missing	15	

¹ Date release 4.0 (May 2015) includes outcomes from follow-up phases that had closed as of July 1, 2014.

² Includes inflammatory, Paget's disease, Phyllodes tumor, and NOS, unknown

³ Includes Paget's disease, and NOS, unknown

⁴ Includes ductal and NOS, unknown tumors, and in situ-occult tumors.

⁵ Includes invasive, in situ, and breast cancer of unknown invasiveness, precedence given to Hispanic ethnicity first, then Black race